Description

The Canadian product safety information for lorazepam and midazolam warn that they should not be used during pregnancy. The Canadian product safety information for phenobarbital warns that during pregnancy the drug’s benefit should be weighed against its risk. Also, restrictions for use in children vary from one drug to another.

Resources

Name	Format	Description	Link
Summary Safety Review - Benzodiazepines and barbiturates - Assessing the potential risk of negative effects on the development of children’s brains (neurodevelopmental disorders)	HTML		https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/benzodiazepines-barbiturates-assessing-potential-risk-negative-effects-development-children-brains.html
Summary Safety Review - Benzodiazepines and barbiturates - Assessing the potential risk of negative effects on the development of children’s brains (neurodevelopmental disorders)	HTML		https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/examens-innocuite/benzodiazepines-barbituriques-evaluation-risque-potentiel-effets-nefastes-developpement-cerveaux-enfants.html

Tags

Topics

Categories